Replies to post #132856 on Biotech Values

[AlpineBV_Miller]

Highlight of ASH was the MD Anderson guys presenting their institutions history with ruxo showing a survival advantage. They really went after the Mayo data. Was a hoot.

I'm not normally a fan of MDACC (see also Advexin), but it's nice to see someone having enough courage to call out (in a public, peer-reviewed format) crappy data from another institution. Much better than the silent backstabbing that usually goes on...